AstraZeneca (AZN) has revealed positive Phase IIa data from the EPICCURE trial of its injection AZD8601, which has been co-developed with Moderna (MRNA). The company said that the trial has met the primary endpoint of safety and tolerability in patients with heart failure. The trial was performed on 11 patients, of which seven were injected with AZD8601 and the remaining received placebo injections. The company said that the injection was directly administered to the myocardium of patients undergoing elective coronary artery bypass grafting (CABG) surgery. (See AstraZeneca stock charts on TipRanks) The Executive Vice-President, BioPharmaceuticals R&D, AstraZeneca, Mene Pangalos, said, “Over one billion heart cells can be lost during a heart attack.
https://www.tipranks.com/news/astrazeneca-moderna-disclose-positive-results-from-epiccure-trial?utm_source=advfn.com&utm_medium=referral
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Moderna Charts.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Moderna Charts.